Studies demonstrated that prophylactic loperamide led to severe constipation during sacituzumab govitecan treatment. Dr. Tolaney advises reserving loperamide strictly for as-needed use, while prioritizing growth factor prophylaxis on days two through four and day eight for patients at high risk of neutropenia.
Managing stomatitis caused by datopotamab deruxtecan requires first assessing whether patients used their prophylactic steroid mouth rinse. Noncompliant patients resolve symptoms quickly once the rinse is initiated, whereas persistent stomatitis despite high compliance requires treatment pauses and subsequent dose reductions.
Triple-negative breast cancer brain metastases frequently present alongside aggressive visceral disease, making pauses for local brain therapy challenging. Emerging trial data indicate topoisomerase-1-directed ADCs penetrate the central nervous system effectively, showing prolonged activity in both parenchymal brain metastases and leptomeningeal disease.
Bispecific antibodies targeting VEGF alongside PD-1 or PD-L1 combined with taxanes achieved 70% to 80% response rates in triple-negative breast cancer. Notably, these combinations demonstrated robust efficacy in PD-L1-negative patients, suggesting bispecific construct synergy overcomes VEGF-driven immunosuppression.
